newsfilter
← Latest News
ACCESS Newswire·

NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

STANS, SWITZERLAND / ACCESSWIRE / September 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patient